<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Contact Us Select Models
Select Models

The patient-derived tumor bank built for the biology others cannot model

We give preclinical oncology researchers a living bank of over 1,400 patient-derived models, many from late-stage, metastatic tumors and characterized across the genome, transcriptome and proteome, so you select on real data and trust that a result reflects the tumor it came from.

The Bank. The Data. The Science

Built on real biology. Proven over 20 years.

The patient-derived tumor bank, the molecular and functional data on every model, and the science we run against both. One source of truth, from model selection to readout.

Models that reflect the patient

Over 1,400 patient-derived models, with more than 700 pretreated tumors, in low-passage, so the biology you study still behaves like the tumor it came from. 

Search the bank

Deep data

Every model carries multi-omic, clinical-response, and proprietary functional data, real tumor biology, ready for computation, so your data scientists train predictive models on ground truth, not inference.

Explore the data ecosystem

The science runs on the same models, by the same team

The same scientific group that characterizes every model, across the genome, transcriptome, and proteome, runs the in vivo and ex vivo work on it. Your data stays consistent from model selection through analysis

See the platforms

Welcome

Meet Champions Oncology

Champions was built on an observation most preclinical research ignores: the patients in your trial will not be treatment naive, but most preclinical models are. Since 2007, we have banked tumors from metastatic, heavily pretreated patients, documented each donor’s treatment history, and characterized models across the genome, transcriptome, and proteome. The result is a preclinical study you can stand behind when the program reaches the clinic.

 

Featured

Popular Content

adc-banner-1

On Demand Webinar

Mastering ADC Model Selection and Navigating Resistance

Antibody-drug conjugates are moving fast, and so is the science behind choosing the right model to develop them. Target expression alone doesn't tell the full story as tumors vary in target density within themselves and across patients, and even a well-selected model can eventually face resistance.

Watch On-Demand Now
iStock-964956320_Lumin Laptop_4_7_22

Lumin

Leverage the Power of Lumin

Champions Oncology's Lumin platform provides researchers with comprehensive, real-time insights into tumor genetics and therapeutic responses. This powerful tool enhances the precision of your oncology research, offering data-driven decisions that speed up development timelines and improve clinical outcomes. 
Access Now

Testimonials

"Champions is a great CRO to partner with. They are always on time, flexible to meet our needs, and are experts in PDX models."

Sr. Director, Biotech Company

"I've been an active Lumin user for over a year now. It's been critical to use this software to analyze and visualize our multi-omic datasets from Champions."

Sr. Bioinformatician, Pharmaceutical Company

Newsroom

What's new at Champions

adc-banner-1

Webinar

Mastering ADC Model Selection and Navigating Resistance

Watch Now
home-odw-tile

Poster

Development of Robust Evaluation of T Cell Subsets with T-Cell Activation In a 3D Tumor–PBMC Co-Culture Model Enables Reliable Phenotyping and Cytotoxicity Assessment

Download Now
case-study-her-pdxo-1

Case Study

Assessment of Clinically Approved HER2-Targeted ADCs in Champions’ TumorGraft3D Models

Access Now
Events_0

Get started

Accelerating Drug Development Through Superior Innovative Solutions